ANAPTYSBIO INC (ANAB)

US0327241065 - Common Stock

18.15  +0.82 (+4.73%)

After market: 18.15 0 (0%)

ANAPTYSBIO INC

NASDAQ:ANAB (9/26/2023, 7:00:00 PM)

After market: 18.15 0 (0%)

18.15

+0.82 (+4.73%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-07 2023-08-07/amc
Earnings (Next)11-06 2023-11-06/amc
Ins Owners0.03%
Inst Owners113.75%
Market Cap481.80M
Shares26.55M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts76.67
IPO01-26 2017-01-26
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ANAB Daily chart

Company Profile

AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 96 full-time employees. The company went IPO on 2017-01-26. The company is focused on developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases. Its product candidate pipeline includes Rosnilimab, which is designed to suppress aberrant T cell driven inflammation by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; ANB032, which is designed to augment BTLA signaling that is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation; ANB033, which targets CD122, the common beta subunit shared by the IL-15 and IL-2 receptors; Imsidolimab, which inhibits the interleukin-36 receptor (IL-36R) and is developed for the treatment of generalized pustular psoriasis (GPP), and Etokimab, which inhibits IL-33 function and acts upstream of key cell types involved in atopy and the subsequent release of Th2 cytokines.

Company Info

ANAPTYSBIO INC

10770 Wateridge Circle, Suite 210

San Diego CALIFORNIA 92121

P: 18583626295.0

CEO: Hamza Suria

Employees: 96

Website: https://www.anaptysbio.com/

ANAB News

News Image6 days ago - Market News VideoRelative Strength Alert For AnaptysBio
News Image9 days ago - Seeking AlphaAnaptysBio announces appointment of John Orwin as chairman of the board (NASDAQ:ANAB)

Clinical-stage biotechnology company AnaptysBio (ANAB) Monday announced the appointment of John Orwin as chairman of AnaptysBio's board of directors.After more than 15 years serving...

News Image9 days ago - AnaptysBio, Inc.AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
News Image9 days ago - AnaptysBio, Inc.AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

After more than 15 years serving on AnaptysBio’s Board of Directors, Jamie Topper, M.D., Ph.D., is stepping down and will serve as an advisor to the Board...

News Image15 days ago - AnaptysBio, Inc.AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
News Image15 days ago - AnaptysBio, Inc.AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit

SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...

ANAB Twits

Here you can normally see the latest stock twits on ANAB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example